<DOC>
	<DOCNO>NCT02720263</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability multiple ascend oral dos ASP4345 patient schizophrenia . In addition , study evaluate pharmacokinetics multiple ascend oral dos ASP4345 patient schizophrenia .</brief_summary>
	<brief_title>A Study Assess Safety , Tolerability , Pharmacokinetics Pharmacodynamics ASP4345 Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Patient diagnosis schizophrenia schizoaffective disorder accord Diagnostic Statistical Manual Mental Disorders , 5th edition criterion . A patient consider operationally stable patient low moderate positive symptom score moderate negative symptom score Positive Negative Syndrome Scale ( PANSS ) : No moderate rating 2 PANSS item P1 , P2 , P3 , P5 , P6 ( positive symptom section ) ; No moderate severity rating negative item , N1 , N2 , N3 , N4 , N5 , N6 , N7 ( negative symptom section ) ; total PANSS score 80 . Patient must ongoing maintenance antipsychotic therapy clozapine ( oral depot ) , stable ( ≤ 25 % change dose ) medication treatment regimen ( approved oral depot formulation risperidone , quetiapine , olanzapine , ziprasidone , brexpiprazole , aripiprazole , paliperidone lurasidone ) ≥ 2 month oral formulation ≥ 3 month depot formulation prior screen , include concomitant psychotropic medication , , trazodone zolpidem sleep . Patient body mass index ( BMI ) range 18.5 40.0 kg/m2 , inclusive , weigh least 50 kg screening . Female patient must nonchildbearing potential : Postmenopausal ( define least 1 year without menses ) prior screen , Documented surgically sterile ( least 1 month prior screen define hysterectomy , bilateral salpingectomy and/or bilateral oophorectomy ) Female patient must donate ovum start screen throughout study period , 28 day final study drug administration . Male patient female spouse/partners childbearing potential must use 2 form highly effective birth control† ( 1 must barrier method‡ ) start screen continue throughout study period 90 day final study drug administration . †Highly effective form birth control include : Consistent correct usage establish oral contraception Injected implant hormonal method contraception Established intrauterine device intrauterine system Bilateral tubal ligation Sexual abstinence consider highly effective method define refrain heterosexual intercourse entire period risk associate study treatment complies prefer usual lifestyle patient . ‡Barrier method birth control include : Condom spermicidal foam/gel/film/cream/suppository Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository Male patient must donate sperm start screen throughout study period 90 day final study drug administration . Patient agree participate another interventional study participate present study , define signing informed consent form end study visit ( ESV ) . Patient negative urine drug screen drug abuse screen check . Female patient pregnant within 6 month prior screen assessment breastfeed within 3 month prior screen . Patient know suspected hypersensitivity ASP4345 component formulation use . Patient previous exposure ASP4345 . Patient history suicide attempt suicidal behavior within 2 year prior screen . Any suicidal ideation meet criteria level 4 5 use CSSRS within last 3 month significant risk commit suicide screen admission clinical unit ( day 2 ) exclude . Patient clinically significant liver chemistry test result aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , alkaline phosphatase ( ALP ) , gamma glutamyl transferase , total bilirubin ( TBL ) result &gt; 1.5 time ULN screen admission clinical unit ( day 2 ) . In case , assessment may repeat . Patient history allergic condition deem clinically significant . Patient history evidence clinically significant cardiovascular , gastrointestinal endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric ( schizophrenia schizoaffective disorder ) , renal and/or major disease malignancy . Patient condition , , make patient unsuitable clinical study participation . Patient diagnose moderate severe tardive dyskinesia , bipolar disorder , major depressive disorder , personality disorder , neuroleptic malignancy syndrome anxiety disorder . Patient has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) fungal ( noncutaneous ) infection within 1 week prior admission clinical unit ( day 2 ) . Patient clinically significant abnormality screen admission clinical unit ( day 2 ) . Patient mean pulse &lt; 40 &gt; 100 bpm ; mean systolic blood pressure ( SBP ) &gt; 160 mmHg ; mean diastolic blood pressure ( DBP ) &gt; 90 mmHg ( vital sign measurement take triplicate patient rest supine position 5 minute ; pulse measure automatically ) screen admission clinical unit ( day 2 ) . If mean blood pressure exceed limit , 1 additional triplicate take day 2 . Patient mean QTcF &gt; 440 msec ( male patient ) &gt; 460 msec ( female patient ) screen admission clinical unit ( day 2 ) . If mean QTcF exceed limit , 1 additional triplicate ECG take day 2 . Patient us prescribe nonprescribed drug ( include vitamin , natural herbal remedy , e.g. , Valerian ) 2 week prior study drug administration , except : 1 . Approved antipsychotic ( risperidone , quetiapine , olanzapine , ziprasidone , brexpiprazole , aripiprazole , paliperidone lurasidone ) , 2 . Approved intermittent use trazodone zolpidem ( le 12 hour prior dose ) , 3 . Approved use concomitant medication treatment hypertension , hyperlipidemia diabetes mellitus , 4 . Occasional use acetaminophen ( 2 g/day ) . Patient history consume 14 unit alcoholic beverage per week within 6 month prior screen history alcoholism drug/chemical/substance abuse within past 2 year prior screen ( Note : 1 unit = 12 ounce beer , 4 ounce wine 1 ounce spirits/hard liquor ) patient test positive alcohol drug abuse ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine opiate ) screen admission clinical unit ( day 2 ) . A patient positive result benzodiazepine may include clinical study , result explain use permit concomitant medication . Patient use strong CYP3A inhibitor ( e.g. , limited : boceprevir , clarithromycin , conivaptan , indinavir , itraconazole , ketoconazole , lopinavir/ritonavir , mibefradil , nefazodone , nelfinavir , posaconazole , ritonavir , saquinavir , telaprevir , telithromycin , voriconazole ) and/or consume grapefruit , grapefruit containing product , Seville orange Seville orange containing product within 72 hour prior admission clinical unit ( day 2 ) . Patient use strong moderate CYP2D6 inhibitor ( e.g. , limited : bupropion , fluoxetine , paroxetine , quinidine , cinacalcet , duloxetine , terbinafine ) within 72 hour prior admission clinical unit ( day 2 ) . Patient regularly us inducer metabolism ( e.g. , limited : barbiturate , rifampin , St. John 's Wort ) 1 month prior admission clinical unit ( day 2 ) . Patient use drug abuse within 3 month prior admission clinical unit ( day 2 ) . Patient significant blood loss , donate 1 unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior admission clinical unit ( day 2 ) . Patient positive serology test hepatitis B surface antigen ( HBsAg ) , hepatitis A virus ( HAV ) antibody ( immunoglobulin M [ IgM ] ) , hepatitis C virus ( HCV ) antibody , human immunodeficiency virus ( HIV ) antibodies type 1 2 screening . Patient participate clinical study treat investigational drug within 28 day 5 half life whichever longer , prior screen . Patient employee Astellas Group Contract Research Organization ( CRO ) involve clinical study . Patient electroconvulsive therapy within 6 month prior screen . Patient history seizure condition risk seizure ; exception , history 1 febrile seizure childhood exclude patient . Patient history head injury clinically significant sequela . Patient experience acute exacerbation schizophrenia require hospitalization within last 3 month . Patient experience acute exacerbation schizophrenia require increase antipsychotic medication ( reference drug dose ) within last 4 week . Patient hearing loss , unable detect 1000 Hz tone present 40 dB . Patient hairstyle would interfere electroencephalogram ( EEG ) record quality . Patient history spine surgery ( intact dura mater ) past year and/or history brain and/or spinal cord injury .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>ASP4345</keyword>
</DOC>